Our study, the first of its kind exploring VTX potential in modulating the NLRP3 inflammasome in a time- and area-specific manner in the brain, could serve as a starting point for further investigations into VTX molecular mechanisms in treating depression and cognitive impairments. The gene discussed is NLRP3; the disease is depressive symptom measurement.